暗記メーカー
ログイン
Drug discovery.
  • Quinn Karylle Fuentes

  • 問題数 60 • 2/27/2024

    記憶度

    完璧

    9

    覚えた

    21

    うろ覚え

    0

    苦手

    0

    未解答

    0

    アカウント登録して、解答結果を保存しよう

    問題一覧

  • 1

    Complementary relationship between the drug molecule and its active site

    Induced fit theory.

  • 2

    maximum biological effect resulting from a drug binding to its target

    Efficacy/ intrinsic activity.

  • 3

    Cocoaine.

    Plant kingdome.

  • 4

    Cephalosporin.

    Microbiological world

  • 5

    Special consideration is given on Orphan drugs (treatment IND) • orphan drug is used to treat orphan disease, or disease that affects fewer than 200,000 people in the US

    IND.

  • 6

    Post-marketing studies and manufacturing scale-up activities take place

    Phase 4.

  • 7

    These studies also evaluate drug metabolism, structure-activity relationships, and the mechanism of action in humans.

    Phase 1.

  • 8

    the intensity of the pharmacologic activity of a structurally specific drug is directly proportional to the number of receptors occupied by the drug

    Occupational theory of response.

  • 9

    The target cells become desensitized and the effect of subsequent exposure to the same concentration of the drug is reduced.

    Desensitization.

  • 10

    What is the opiate u receptors antagonist

    Naloxone.

  • 11

    Large libraries of compounds are tested for their ability to modify the target capable of examining 15,000 chemical compounds a week using 10 – 20 bioassays.

    High throughput screening.

  • 12

    Protein.

    Animal source.

  • 13

    Quinine

    Plant kingdom.

  • 14

    Permit to market drug product

    NDA.

  • 15

    an increasing number of new receptors and enzymes potential drug targets

    Genome project.

  • 16

    drugs activity is tested on isolated tissues, cells, enzymes.

    In vitro test.

  • 17

    Somatostatin. (protein)

    Animal source.

  • 18

    Modification of drug formulation as obtained from manufacturing scale-up and validation process may be done

    Phase 4.

  • 19

    A popular term for a generic drug with an identical formulation and stated indications as a drug previously approved by the FDA.

    Me-too-Drugs.

  • 20

    Glucagon (Protein)

    Animal source.

  • 21

    vaccines (living or killed microorganisms)

    Biological sources

  • 22

    1000-3000 with the target illness.

    Phase 3

  • 23

    Conduct short-term toxicity studies ranging from 2 weeks to 3 months.

    At preclinical stage.

  • 24

    The study of the interaction of the drugs with cells.

    Pharmacodynamics.

  • 25

    100-300 Suffer from the target illness

    Phase 2.

  • 26

    Aminoglycosides.

    Microbial world.

  • 27

    Submitted to FDA à Review by FDA for 30 days

    IND.

  • 28

    Penicillin.

    Microbiological world.

  • 29

    • Failure during Phase II testing is common • After phase 2, sponsors meet with the FDA (True/False)

    True

  • 30

    This phase of testing also helps determine the common short-term side effects and risks associated with the drug.

    Phase 2.

  • 31

    What is B1-adrenoceptors Agonist

    Isoprenaline.

  • 32

    Amphotericin B.

    Lipid.

  • 33

    Tetracycline.

    Microbiological world.

  • 34

    These studies also provide an adequate basis for extrapolating the results to the general population and transmitting that information in the physician labeling

    Phase 3.

  • 35

    Prewingkle

    Plant kingdom.

  • 36

    Cell or group of cells specialized to detect changes in the environment and trigger impulses in the sensory nervous system

    Receptors.

  • 37

    Reserpine.

    Plant kingdom.

  • 38

    a molecule that binds to a receptor

    Ligand.

  • 39

    Generic drug . A company needs to show the FDA that the drug is bioequivalent to the innovator drug

    NDA.

  • 40

    completely complementary relationship between the drug molecule and a specific area on the surface of the receptor molecule

    Lock and key theory.

  • 41

    Heparin (Polysaccharide)

    Animal source.

  • 42

    What is the opiate u receptors agonist

    Morphine.

  • 43

    Bile acids.

    Animal source.

  • 44

    Filed before drug may be given to human (clinical trials)

    IND.

  • 45

    In. vitro and in vivo testing, determination of LD 50.

    Toxicity testing.

  • 46

    Lovastatin.

    Microbiological world.

  • 47

    Dating back to the cavemen following their instincts to survive or preserve their lives, drugs already exist in various forms.

    Drug discover before.

  • 48

    Focusing on the financial return

    1.

  • 49

    Used as receptors.

    Protein.

  • 50

    An increased-concentration of the drug is required to produce an effect of the same magnitude as the initial exposure with a smaller drug concentration (T/F)

    True.

  • 51

    A compound showing a desired pharmacological property which can be used to initiate a medicinal chemistry project

    Finding a lead compound.

  • 52

    What is the H1 and H2 receptors agonist

    Histamine.

  • 53

    What is B2-adrenoceptors Agonist.

    Salbutamol.

  • 54

    Safety and effectiveness

    Phase 2.

  • 55

    The general area of study concerned with the formulation, manufacturing, stability, and effectiveness of a pharmaceutical dosage form

    Pharmaceuticals.

  • 56

    Dynamic interactions between drug molecules and cellular components

    Drug action.

  • 57

    The handling of a drug within the body. it includes the adme process.

    Pharmacokinetics.

  • 58

    Protein catalysts are produced by living cells by acting as a surface or focus for the reaction, bringing the substrate(s) together and holding them in the best position for the reaction.

    Enzyme.

  • 59

    These studies are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug.

    Phase 3.

  • 60

    20-80 healthy volunteer.

    Phase 1.

  • 61

    submitted for review and approval after the completion of the clinical trials and requirements have been met

    NDA.

  • 62

    inducing a clinical condition and treated with the test drug

    In vivo test.

  • 63

    What is the H1 receptors antagonist

    Mepyramine.

  • 64

    DNA and RNA acting as a drug target.

    Nucleic acids target.

  • 65

    Even before the synthetic, target-based, and selective medicinal agents, remedies were abundantly provided by various plant sources more commonly referred to as herbal remedies

    Drug development before.

  • 66

    What is B2-adrenoceptors Antagonist

    Propanolol.

  • 67

    Result of downregulation

    Desensitization.

  • 68

    Used as molecular tag.

    Carbohydrates.

  • 69

    For safety

    Phase 1

  • 70

    Science of the properties of the drugs and it's effect in the body.

    Pharmacology.

  • 71

    Paclitaxel.

    Plant kingdom.

  • 72

    atoms and functional groups required for a specific pharmacological activity, and their relative positions in space

    Pharmacophore.

  • 73

    Estrogens.

    Animal source.

  • 74

    Safety, effectiveness and dosage

    Phase 3.

  • 75

    What is the H2 receptors antagonist

    Ranitidine.

  • 76

    What is B1-adrenoceptors Antagonist

    Atenolol

  • 77

    Morphine

    Plant kingdom.

  • 78

    Ways of discovering a lead compound

    Finding a lead compound.

  • 79

    Caused by continuous prolonged exposure of receptors to drugs that disrupt the homeostatic equilibrium and result in altered levels of the receptors.

    Down regulation.

  • 80

    In vivo and in vitro.

    Identifying bioassay.

  • 81

    Receptors, enzymes, and nucleic acids

    2.

  • 82

    Filed before drug may be given to human (clinical trials)

    Investigational new drug application.

  • 83

    These studies are designed to determine the metabolic and pharmacological actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness

    Phase 1.

  • 84

    measure of how strongly a drug binds to a receptor

    Affinity.

  • 85

    The DISCOVERY phase includes synthesis, isolation, fermentation, screening, and SAR studies

    Drug development process.

  • 86

    Protein in nature and embedded in the cell membrane

    Receptors.

  • 87

    Chemical and physical characterization, pharmacology, pharmacokinetics, pharmacodynamics, pharmaceutics, analytical studies, toxicology

    Pre clinical studies.